The company behind a new GLP-1 pill is betting $6.5 billion on Houston
Eli Lilly has broken ground on a $6.5 billion manufacturing plant in Houston's Generation Park, scheduled for completion by 2030. CEO Dave Ricks reported that the company's GLP-1 pill, Foundayo, now captures one-third of new patients starting that medication. Lilly is also seeing significant growth among seniors, with Ricks stating 70% of the 700,000 new Medicare patients starting GLP-1s are using Lilly products. The company is simultaneously ramping up production and targeting foreign markets to expand Foundayo's reach.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Eli Lilly is spending $6.5 billion on a new facility in Houston.
- ✓ The Houston plant is planned for 2030.
- ✓ CEO Dave Ricks stated one-third of new GLP-1 pill patients are taking Foundayo.
- ✓ Lilly has announced ten U.S. manufacturing sites since 2020.
What changed
Eli Lilly broke ground on a $6.5 billion Houston plant and reported market share data for Foundayo and Medicare patients.
Live updates
-
Eli Lilly begins construction on $6.5 billion Houston facility
Eli Lilly has broken ground on a $6.5 billion manufacturing plant in Houston's Generation Park, scheduled for completion by 2030. CEO Dave Ricks reported that the company's GLP-1 pill, Foundayo, now captures one-third of new patients starting that medication. Lilly is also seeing significant growth among seniors, with Ricks stating 70% of the 700,000 new Medicare patients starting GLP-1s are using Lilly products. The company is simultaneously ramping up production and targeting foreign markets to expand Foundayo's reach.
Why it matters
This expansion is part of a larger domestic strategy, marking one of ten U.S. manufacturing sites announced since 2020. The growth follows increased Medicare coverage for weight-loss medications.
What is confirmed
- Eli Lilly is spending $6.5 billion on a new facility in Houston.
- The Houston plant is planned for 2030.
- CEO Dave Ricks stated one-third of new GLP-1 pill patients are taking Foundayo.
- Lilly has announced ten U.S. manufacturing sites since 2020.
- CEO Dave Ricks said 70% of 700,000 new seniors starting GLP-1s after Medicare coverage are on Lilly drugs.
Still unconfirmed
- Eli Lilly announced a $15 million contribution to San Jacinto College.
What to watch next
- Progress updates on the Houston facility construction toward the 2030 goal
- Foundayo adoption rates in foreign markets
- Changes in Medicare coverage impact on GLP-1 market share
confidence 100%Sources used for this update (11)
- CNBC — Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- KHOU — Eli Lilly is breaking ground in Houston on a facility planned for 2030
- houstonchronicle.com — The company behind a new GLP-1 pill is betting $6.5 billion on Houston
- Seeking Alpha — Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets
- finance.yahoo.com — Lilly CEO Dave Ricks says Foundayo winning new pill patients
- Axios — Eli Lilly breaks ground on $6.5B Houston plant
- CNBC — Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
- Eli Lilly — Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
- Yahoo Finance — LLY Stock Gains As CEO Says Foundayo Wins One-Third of New GLP-1 Pill Starts, Breaks Ground On $6.5B Houston Plant
- abc13.com — Lilly breaks ground in Generation Park, announces $15M contribution to San Jacinto College
- qz.com — Eli Lilly is capturing 70% of new Medicare patients on weight-loss drugs, CEO says
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community